Genprex up on encouraging early-stage data on lung cancer therapy

Genprex

26/05/2023 11:29

** Shares of gene therapy developer Genprex Inc  GNPX.O  up
4.5% at $0.88 premarket
    ** Co reports positive data from early stage study testing
experimental therapy Reqorsa in patients with a type of lung
cancer
    ** Study evaluated Reqorsa in combination with AstraZeneca
Plc's  AZN.L  Tagrisso in late-stage non-small cell lung cancer
    ** Observed Reqorsa to be generally well tolerated with
encouraging evidence of efficacy - GNPX
    ** Data published in an abstract at the 2023 American
Society of Clinical Oncology annual meeting
    ** Stock down 41% YTD

 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))